Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Defer

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Revue Neurologique|September 30, 2022
Secondary progressive multiple sclerosis: A national consensus paper on diagnostic criteriaJ Ciron, A Gueguen, A Al Khedr, et al.
Neurology|December 29, 2005
Idiopathic acute transverse myelitis: application of the recent diagnostic criteriaJ de Seze, C Lanctin, C Lebrun, et al.
European Journal of Neurology|September 30, 2017
High-dose transdermal nicotine in Parkinson's disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 studyG Villafane, C Thiriez, E Audureau, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 18, 2011
High-risk syndrome for neuromyelitis optica: a descriptive and comparative studyN Collongues, R Marignier, H Zéphir, et al.
Journal of Neurology|May 2, 2015
Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric studyA Siri, Clarisse Carra-Dalliere, X Ayrignac, et al.
European Journal of Neurology|July 31, 2013
A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohortO Outteryck, J C Ongagna, B Brochet, et al.
Neurology|March 3, 2010
Neuromyelitis optica in France: a multicenter study of 125 patientsN Collongues, R Marignier, H Zéphir, et al.
BMC Medical Research Methodology|May 31, 2022
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisM Lefort, S Sharmin, J B Andersen, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Revue Neurologique|September 30, 2022
Secondary progressive multiple sclerosis: A national consensus paper on diagnostic criteriaJ Ciron, A Gueguen, A Al Khedr, et al.
Neurology|December 29, 2005
Idiopathic acute transverse myelitis: application of the recent diagnostic criteriaJ de Seze, C Lanctin, C Lebrun, et al.
European Journal of Neurology|September 30, 2017
High-dose transdermal nicotine in Parkinson's disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 studyG Villafane, C Thiriez, E Audureau, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 18, 2011
High-risk syndrome for neuromyelitis optica: a descriptive and comparative studyN Collongues, R Marignier, H Zéphir, et al.
Journal of Neurology|May 2, 2015
Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric studyA Siri, Clarisse Carra-Dalliere, X Ayrignac, et al.
European Journal of Neurology|July 31, 2013
A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohortO Outteryck, J C Ongagna, B Brochet, et al.
Neurology|March 3, 2010
Neuromyelitis optica in France: a multicenter study of 125 patientsN Collongues, R Marignier, H Zéphir, et al.
BMC Medical Research Methodology|May 31, 2022
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisM Lefort, S Sharmin, J B Andersen, et al.
Pageof 7